Why Neurocrine Biosciences, Inc. (NBIX) stock moved
Neurocrine Biosciences, Inc. (NBIX) shares fell 4.4% to $135.13 as of October 14, 2026, a moderate decline from the prior close of $141.37. BestStocks flagged the session as a major change for NBIX. Below, we break down what changed for NBIX, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
NBIX fell 4.4% to $135.13
NBIX fell 4.4% in its latest session, moving from $141.37 to $135.13.
What it means for Neurocrine Biosciences, Inc. investors
For Neurocrine Biosciences, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Neurocrine Biosciences, Inc. (NBIX) moved +3.63% from $179.00 to $185.50 on 2026-07-30, reaching a new 30-day high on modestly elevated volume (1.9x the 5-day average). Weighing against that: Material negative event; Negative session, down 4.4%. Wall Street's consensus price target sits at $204.18, implying +51.1% upside from $135.13. BestStocks rates the overall signal quality low (57/100). With earnings roughly 19 days out, the next report is the most likely near-term test of the move.
NBIX price reaction
NBIX last traded at $135.13, down $6.24 (-4.41%) from the previous close of $141.37. The session traded on 1.2× average volume (normal), so participation was unremarkable. Over the past month the stock has ranged between $135.13 and $157.22, and it currently sits about 0% of the way up that band.
Bullish and bearish analyst opinions on Neurocrine Biosciences, Inc. (NBIX)
The consensus analyst price target on Neurocrine Biosciences, Inc. (NBIX) is $204.18, 51.1% above the recent $135.13. Over the past 90 days analysts logged 0 upgrades, 20 maintains, and 0 downgrades. Here is how the bullish and bearish cases on NBIX line up.
The bullish case
- Wall Street's consensus price target of $204.18 implies +51.1% upside from $135.13.
- The Street's most bullish target is $230.00 (+70.2%).
- Neurocrine Biosciences, Inc. (NBIX) moved +3.63% from $179.00 to $185.50 on 2026-07-30, reaching a new 30-day high on modestly elevated volume (1.9x the 5-day average).
The bearish case
- Material negative event.
- Negative session, down 4.4%.
- Neurocrine Biosciences fell 3.11% to $136.97 ahead of third-quarter 2026 earnings on October 27, with the company having announced its earnings call for November 2 on October 12 (PRNewswire).
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 14, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for NBIX
In-depth NBIX event analyses
Frequently asked questions about NBIX
Why did Neurocrine Biosciences, Inc. (NBIX) stock move?
NBIX fell 4.4% to $135.13. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did NBIX stock fall?
NBIX lost 4.41% ($6.24) versus the prior close of $141.37, last trading at $135.13 on 1.2× average volume.
When is Neurocrine Biosciences, Inc.'s next earnings date?
NBIX's next earnings report is estimated for 2026-11-02 — about 19 days away.
What is the analyst price target for NBIX?
The consensus analyst price target for NBIX is $204.18, about 51.1% above the current $135.13. Over the past 90 days, analysts recorded 0 upgrades, 20 maintains, and 0 downgrades.
How BestStocks tracks NBIX
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared NBIX-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for NBIX, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 14, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.